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Abstract Rat uterine stromal cells (UIII) express pancreatic 
type PLA2 (PLA2-I) receptor and internalize the enzyme bound 
to receptors. Here, we investigate the proliferating effect and 
alterations in binding of PLA2-I. There is a dramatic decline in 
PLA2-I binding in Um cells as they progress from a non- 
confluent proliferating state (40,000 sites/cell) to a confluent 
state (1300 sites/cell). Intracellular concentration of PLA2-I 
changed with the alteration in binding, suggesting that regulation 
in the PLA2 binding capacity may have important implications in 
growth control mechanisms. 
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1. Introduction 
Phospholipases A2 (PLA2 ; EC 3.1.1.4) are lipolytic enzymes 
that hydrolyze the sn-2 acyl ester bound in glycerophospho- 
lipids [1]. Many forms of PLA2 enzymes have been described 
and classified into several groups [2 5]. Type I, II and III 
PLA2 are low molecular weight (13-18 kDa), extracellular 
enzymes, including pancreatic and cobra venom PLA2 (type 
I), rattle snake and inflammatory PLA2 (type II) and bee 
venom (type III). Intracellular cytosolic PLA2, on the other 
hand, belong to different groups, including the 85 kDa (type 
IV) and 40-60 kDa enzymes [5]. In recent years, evidence for 
the involvement of distinct types of PLA2 in cell proliferation 
has been obtained. Particularly, type I PLA2 has been shown 
to stimulate proliferation of 3T3 cells via a specific membrane 
receptor, and the contribution of Arita's group in this re- 
search field was determinant [6-8]. This proliferative effect 
can be clearly distinguished from its phospholipid hydrolyzing 
activity. 
We have recently established a stromal cell line (Urn) de- 
rived from normal rat uterus which has retained some of the 
characteristics of uterine stromal cells, particularly progester- 
one and prolactine receptor expression, progesterone regula- 
tion of growth [9] and production of prostaglandins under 
hormonal regulation [10]. Immunocytochemistry studies re- 
vealed that Um cells express the pancreatic type PLA2 [10]. 
Proliferation of Um cells was not affected by inhibitors of 
cyclooxygenase and lipoxygenases but was reduced and even 
arrested by different PLA2 inhibitors [11]. Moreover, we have 
recently demonstrated that Uni cells express specific mere- 
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brane receptors for PLA2-I and that binding of PLA2-I to 
its specific receptor is associated with intemalization of the 
enzyme [12], which seems to be a general mechanism of mem- 
brane receptors for low molecular weight PLA2 [13]. Since, in 
our experimental system, the internalized PLA2 is not rapidly 
degraded, supporting the hypothesis that this enzyme is in- 
volved in the control of Uni cell functioning, we investigated 
the proliferative ffect of PLA2-I and the relationship between 
the number of PLA2-I binding sites and the proliferative state 
of these non-transformed cells. 
2. Material and methods 
2.1. Chemicals 
Tissue culture medium (M199), phosphate-buffered saline (PBS), 
L-glutamine, penicillin, streptomycin were obtained from TechGen 
International (Les Ulis, France), fetal calf serum (FCS) from GIBCO 
(Cergy-Pontoise, France). Trypsin 1 ×, trypan blue, PLA2 from por- 
cine and bovine pancreas and from bee, Crotalus atrox and Naja 
mocambique moeambique venom were purchased from Sigma Chimie 
(St. Quentin Fallavier, France). Iodo beads were purchased from 
Pierce Chemical Co. Bis-benzimide H 33258 was from Fluka. [6- 
3H]thymidine (26 Ci/mmol) was obtained from Amersham (Les 
Ulis, France). Sodium (12~I) iodine (cartier-free, 100 mCi/ml) was 
from Du Pont/New England Nuclear (Les Ulis, France). All other 
chemicals were analytical grade. 
2.2. Cell culture 
For stock culture, rat uterine stromal cells (Urn cells) were grown in 
Falcon plastic flasks (75 cm 2) in an air/CO2 (95 : 5%) humidified at- 
mosphere at 37°C. M199 medium was supplemented with 10% FCS, 
2 mM L-glutamine, 100 U/ml penicillin and 100 ~tg/ml streptomycin. 
Medium was changed every 48 h. Confluent cells were subcultured by 
incubation with 0.25% trypsin, centrifuged and seeded at a ratio of 
1 : 2. Cell viability, determined by the trypan blue exclusion method, 
was consistently greater than 95%. 
2.3. Growth experiments 
Confluent cells from stock culture (50th-58th passages) were tryp- 
sinized inoculated in 24-well plates (,-~5× 104 cells/well) in medium 
M199 with 1% FCS. Twenty-four hours after seeding, the medium 
with unattached cells was removed and fresh medium with or without 
the different PLA2 was added. An index of cell number was achieved 
by assay of total DNA content per well after 48 h of culture, using a 
fluorimetric procedure [14]. The cells were washed twice with PBS. 
Then 2 ml of homogenization buffer (50 mM Na2 HPO4, 2 M 
NaCI, 2 mM EDTA, pH 7.4) were added to each well. Well contents 
were briefly sonicated using a microprobe. Aliquots of the homoge- 
nate were mixed with buffer containing the ftuorochrome H 33258 to 
a final concentration of 0.1 ~tg/ml. Fluorescence measurements were 
made 15 min after mixing, using a Jobin-Yvon spectrofluorimeter, 
with calf thymus DNA as a standard. For thymidine incorporation, 
1 ~tCi of [3H]thymidine was added to each well and plates were in- 
cubated for a further 24 h. The medium was removed, and the cells 
were washed twice with 1 ml of ice-cold PBS. Then 2 ml of ice-cold 
10% trichloroacetic acid (TCA) were added to each well. Well con- 
tents were briefly sonicated using a microprobe, incubated for 30 min 
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at 0°C, removed and filtered through a nitrocellulose membrane filter 
(Millipore 0.45 gm, with 2.5 cm diameter). The filter was then washed 
3 times with 5 ml of ice-cold 5% TCA, and the radioactivity asso- 
ciated with the filter was counted by liquid scintillation using 8 ml of 
Ultimagold (Packard). 
2.4. Binding studies 
For binding studies, UII  I cells from stock cultures were seeded at 
different densities and grown for 72 h in medium M199 with 10% FCS 
in 60 mm Petri dishes. The cells were washed once with 2.5 ml of 
binding medium, consisting of M199 medium containing 0.1% (w/v) 
bovine serum albumin and 50 mM HEPES buffer, pH 7.2. Culture 
dishes received 1.5 ml of binding medium, and the cells were then 
incubated with 20 nM iodinated PLA2 in the presence or absence of 
a 100-fold molar excess of non-radioactive PLA2 as a competitor. 
Iodination of porcine pancreatic PLA2 was carried out using the 
Iodo beads iodinating reagent, as described previously [12]. The spe- 
cific radioactivity of iodinated PLA2 was 100-200 dproJfmol. The 
incubation with ligand was performed 2 h at 4°C or 90 rain at 
37°C. At the end of the incubation, the binding medium was removed, 
and cells were washed 5 times with 2.5 ml of PBS buffer at 4°C. The 
radioactivity associated with U~I cells was then determined after sol- 
ubilization with 1 ml of 1 N NaOH and samples neutralization with 1 
ml of 1 N HC1. The specific binding of PLA~ to Um cells was deter- 
mined by subtraction of the radioactivity measured in cells incubated 
in the presence of competitor f om that of paired samples incubated in 
its absence. 
2.5. Statistical analysis 
Non-parametric statistics (Kruskal-Wallis test) were used. A com- 
parison was considered not significant when the calculated P value 
exceeded 5%. 
3. Results and discussion 
Our results show that porcine PLA2-I exerts a significant 
proliferative ffect on UIII cells grown in medium 199 supple- 
mented with 1% FCS, a serum concentrat ion that allows a 
very slow proliferating state [9]. Both DNA content per well 
(Fig. la) and [aH]thymidine incorporat ion (Fig. lb) were in- 
creased after 2 days of culture. These effects were dose-de- 
pendent and significant (P < 0.05) at the optimal concentra- 
tion of 10 nM, Supplementation of the culture medium with 
concentrations of PLA2-I (~>50 nM) reduced the cell viability 
(data not shown). Bee, Crotalus and Naja venom PLA2s, 
which have no affinity for the pancreatic PLA2 receptor pre- 
sent in UIH cell membranes [12], showed no growth promoting 
effect (Table 1). The bovine pancreatic PLA2, a l though very 
similar to the porcine enzyme, was also inactive. This unex- 
pected result could be related to the high specificity of UII~ cell 
binding sites towards porcine pancreatic PLA2. As a matter of 
fact, we have shown from displacement curves that the affinity 
of bovine PLA2-I is at least 5-fold lower than that of the 
porcine enzyme [12]. A competitive ffect was only observed 
Table 1 
Effect of various secreted PLA2 on UI I  I cell proliferation 
PLA2(10 nM) DNA(ng/well) 
None 643 + 10 
Porcine pancreas 903 + 56* 
Bovine pancreas 638 + 91 
Bee venom 735 + 77 
Crotalus venom 723 + 40 
Naja venom 715 + 46 
Um cells were grown for 48 h in the presence of various secreted 
PLA2 at a concentration of I0 nM as indicated in Section 2. Results 
are expressed as the mean _+ S.D. of three independent determinations. 
*Significantly different (P < 0.05) from control values. 
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Fig. 1. Effect of pancreatic PLA2 on UIII cell proliferation. Data are 
expressed as percent of control values (no PLA2 added) and are the 
mean + standard eviation of three independent experiments. Um 
cells were grown on 24-well plates in M199 medium supplemented 
with 1% FCS, and the DNA content per well (a) or [3H]thymidine 
incorporation (b) were determined as described in Section 2, 48 h 
after supplementation f the culture medium with 0.1, 1 or 10 nM 
PLA2. *Significantly different (P< 0.05) from control values. 
at concentrations which reduced the viability of cells grown 
during 48 h in such supplemented medium. These results agree 
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Fig. 2. Effect of aristolochic acid on PLA2-I binding in UIII cells. Specific binding of iodinated porcine PLA2-I was measured as described in 
Section 2 in the presence of indicated concentrations of aristolochic acid in the binding medium. Data are expressed as percent of control val- 
ues (2217+ 181 fmol/mg DNA) and are the mean + standard eviation of three independent experiments. 
with previously published data obtained on various trans- 
formed cellular models such as: Swiss 3T3 cells [6,15], rat 
aortic smooth muscle cells and rat synovial cells [16], rat 
chondrocytes [7] as well as on cancer cell lines such as A 
549 lung adenocarcinoma cells [17] or human pancreatic an- 
cer cells [18]. Moreover, they are consistent with the observa- 
tion that PLA2-I-induced proliferation is dependent on speci- 
fic membrane receptor binding. We have shown previously 
that the PLA2 inhibitor aristolochic acid, which binds directly 
to PLA2 and alters the c~-helical content of the protein [19], 
exerts a potent antiproliferative effect on Um cells at micro- 
molar concentrations [11]. We tested the hypothesis that this 
effect was related to change in binding activity of 125I-labeled 
PLA~-I. As shown in Fig. 2, addition of aristolochic acid to 
the binding medium reduced the binding activity of porcine 
PLA2-I in a dose-dependent manner with an IC50 of about 
3 gM, that agrees with its antiproliferative effect. It should be 
noted that dexamethasone, another PLA2 inhibitor that re- 
duced Uiu cell proliferation at 100 gM [11], also reduces 
PLA2-I binding activity by about 60% at this concentration 
[161. 
In order to strengthen the relationship between PLA2-I 
binding sites and UII I cell proliferation, we next investigated 
growth-dependent alterations in PLA2-I binding. Results, 
summarized in Fig. 3, show that there is a drastic decrease 
in the number of specific PLA2-I binding sites as UII I cells 
progress from an actively proliferating state to a contact-in- 
hibited monolayer. The number of PLA2-I receptors de- 
creased uring the growth of Uni cells from about 40,000 sites 
per cell in the earlier stages of proliferation to about 1300 sites 
per cell in confluent cultures. This decrease in the binding of 
PLA2-I was not simply a consequence of increasing time of 
culture, since in these experiments Uni cells were grown dur- 
ing the same period after seeding at different densities. Since 
PLA2-I is internalized after binding to its specific receptor 
[12], we studied the difference in internalization between con- 
fluent and non-confluent cells. We took advantage of the fact 
that cell washing with an acidic buffer removes PLA2 bound 
to plasma membrane receptors [16] and we measured the 
PLA2 levels in the extracellular (acid-soluble) and intracellular 
(acid-resistant) compartments of Um cells. The data reported 
in Table 2 show that, after 90 min of incubation at 37°C, the 
levels of intracellular PLA2 are about 4-fold higher than those 
Table 2 
Membrane-bound and intracellular levels of PLA2-I in preconfluent 
and confluent Uni cells 
Confluent(n =5) Non-confluent@ = 3) 
Membrane-bound 364 + 55 1352 + 130 
Intracellular 1660 + 228 6380 + 141 
Confluent and non-confluent cells were incubated for 90 min at 37°C 
with 20 nM iodinated porcine pancreatic PLA2 in the presence or 
absence of a 100-fold molar excess of unlabelled competitor. At the 
end of incubation, cells were washed 5 times with 2.5 ml of PBS buffer 
and were further incubated with 2.5 ml of 50 mM glycine buffer, pH 
3.0, containing 0.1 M NaC1, for 10 min at 4°C. The acidic buffer was 
then collected and used to determine the acidic-extractable, mem- 
brane-bound radioactivity. Cells were then solubilized with 1 N 
NaOH to measure the residual acid-resistant, intracellular radioactiv- 
ity. Measurements were made in triplicate in n independent experi- 
ments. Data are expressed as fmol of iodinated PLA2 bound per mg 
DNA and are the mean _+ S.D. 
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Fig. 3. Effect of cell density on specific binding of porcine pancreat- 
ic PLA2 in Um cells. Binding studies were performed as indicated 
in Section 2. Specific binding was calculated by subtraction of bind- 
ing obtained in the presence of unlabelled competitor from that 
found in its absence. 
detectable in the extracellular counterpart both in confluent 
(4.6 + 0.7) and in non-confluent cells (4.8 + 0.4). These results 
demonstrate hat, at physiological temperature, PLA2 is inter- 
nalized at the same rate (about three molecules of PLA2-I per 
receptor and per hour) in confluent and non-confluent Um 
cells. Thus, decrease in the number of specific PLA2-I mem- 
brane receptors results in a correlative reduction of intracel- 
lular concentration of PLA2-I. This regulation in the number 
of PLA2-I receptors might be a physiologically relevant mech- 
anism implicated in the phenomenon of contact inhibition. 
Many phenotypic hanges occur in cultured cells as they 
progress from an actively dividing state to a contact inhibited 
monolayer. For example, metabolism of arachidonic acid in 
particular is highly modified and its release from phospholip- 
ids decreases when cells become confluent [20,21]. Changes in 
lipid metabolism occur in the process of normal or trans- 
formed cell proliferation [22,23] and variations in the cellular 
concentration of some particular phospholipids are even con- 
sidered as cancer markers. The effects of eicosanoids on cell 
proliferation have also often been described in normal as well 
as in transformed cell lines [24-27]. All these results imply 
specific changes in PLA2 activity rather than variations in 
the expression of PLA2 itself. However, the secretory phos- 
pholipase A2 genes have been recently described as a novel 
class of genes that influence tumor susceptibility [28]. More- 
over, cancer cells may overexpress some receptors activated by 
specific growth factors such as EGF receptors, for example in 
the case of human pancreatic carcinoma cells [29]. Our results 
confirm the proliferative ffect of PLA2-I and indicate that the 
level of membrane PLA2-I receptors varies according to the 
proliferative state of Uni cells. They suggest hat, after bind- 
ing to its receptor, internalized PLA2-I might be involved, as a 
signaling molecule, in the control of Uin cell proliferation and 
we may speculate that the level of PLA2-I receptor expression 
might be a new cell cancer marker. 
Acknowledgements: We are grateful to Ms. V6ronique Pommatau- 
Deschamps for her excellent secretarial assistance and Ms. Claudine 
Raffy for her excellent technical assistance. This work was supported 
by INSERM. 
References 
[1] Dennis, E.A. (1983) in: The Enzymes (Boyer, P.D., ed.), 3rd 
edn., Vol. 16, pp. 307-353, Academic Press, New York. 
[2] Glaser, K.B., Mobilio, D., Chang, J.Y. and Senko, N. (1993) 
Trends Pharmacol. Sci. 14, 92-98. 
[3] Kudo, I., Murakami, M., Hara, S. and Inoue, K. (1993) Biochim. 
Biophys. Acta 117, 217-23l. 
[4] Mayer, R.J. and Marshall, L.A. (1993) FASEB J. 7, 339-348. 
[5] Mukherjee, A.B., Miele, L. and Pattabiraman, N. (1994) Bio- 
chem. Pharmacol. 48, 1 10. 
[6] Arita, H., Hanasaki, K., Nakano, T., Oka, S., Teraoka, H. and 
Matsumoto, K. (1991) J. Biol. Chem. 266, 19139-19141. 
[7] Kishino, J., Tohkin, M. and Arita, H. (1992) Biochem. Biophys. 
Res. Commun. 186, 1025-1031. 
[8] Ohara, O., Ishizaki, J. and Arita, H. (1995) Prog. Lipid Res. 34, 
117-138. 
[9] Cohen, H., Pageaux, J.F., Melinand, C., Fayard, J.M. and Lau- 
gier, C. (1993) Eur. J. Cell Biol. 61, 116-125. 
[10] Prigent, A., Fayard, J.M., Pageaux, J.F., Lagarde, M., Laugier, 
C. and Cohen, H. (1994) Prostaglandins 47, 451-466. 
[11] Fayard, J.M., Tessier, C., Cohen, H., Lagarde, M., Pageaux, J.F. 
and Laugier, C. (1994) Eur. J. Pharmacol. 251,281-289. 
[12] Rossini, G.P., Fayard, J.M., Tessier, C. and Laugier, C. (1996) 
Biochem. J. 315, 1007-1014. 
[13] Zvaritch, E., Lambeau, G. and Lazdunski, M. (1996) J. Bio. 
Chem. 271,250-257. 
[14] Labarca, C. and Paigen, K. (1980) Anal. Biochem. 102, 344-352. 
[15] Kurizaki, T., Egami, H., Murata, K., Kiyohara, H., Okazaki, S., 
Yoshida, N. and Ogawa, M. (1992) Res. Commun. Chem. 
Pathol. Pharmacol. 78, 39-45. 
[16] Hanasaki, K. and Arita, H. (1992) J. Biol. Chem. 267, 6414- 
6420. 
[17] Tokumoto, H., Croxtall, J.D., Choudhury, Q. and Flower, R.J. 
(1993) Biochim. Biophys. Acta 1164, 236-242. 
[18] Hanada, K., Kinoshita, E., Itoh, M., Hirata, M., Kajiyama, G. 
and Sugiyama, M. (1995) FEBS Lett. 373, 85-87. 
[19] Vishwanath, B.S. and Gowda, T.V. (1987) Toxicon 25, 929-937. 
[20] Whatley, R.E., Satoh, K., Zimmerman, G.A., Mclntyre, T.M. 
and Prescott, S.M. (1994) J. Clin. Invest. 94, 1889 1900. 
[21] Denizot, Y., Najid, A. and Rigaud, M. (1993) Cancer Lett. 68, 
199-205. 
[22] Piomelli, D. (1993) Curr. Opin. Cell Biol. 5, 274-280. 
[23] Welsh, C.W. (1995) Free Rad. Biol. Med. 18, 757-773. 
[24] Powis, G., Hill, S.R., Frew, T.J. and Sherill, K.W. (1995) Med. 
Res. Rev. 145 121-138. 
[25] Ledwozyw, A. and Lutnicki, K. (1992) Acta Physiol. Hungarica 
79, 381-387. 
[26] Butcher, R.D., Wojcik, S.J., Lints, T., Wilson, T., Schoffield, 
P.C. and Ralph, R. (1993) Cancer Res. 53, 3405-3410. 
[27] Bashir, N., Kuhen, K. and Taub, M. (1992) In vitro Cell. Dev. 
Biol. 28A, 663-668. 
[28] MacPhee, M., Chepenik, K.P., Lidell, R.A., Nelson, K.K., 
Siracusa, L.D. and Buchberg, A.M. (1995) Cell 81,957-966. 
[29] Korc, M., Meltzer, P. and Trent, J. (1986) Proc. Natl. Sci. USA 
83, 5141 5144. 
